Publication date: Jun 23, 2026
The workshop on ‘Reactive and therapy induced BM changes linked to systemic infectious and non-infectious disorders including MAS/HLH’ of the 22nd meeting of the European Association for Haematopathology held in Dubrovnik, 2024, included 58 cases. These encompassed a broad range of infections, autoimmune disorders, malignancies and therapy-effects, or a combination of these factors, of which 28 had an associated Hemophagocytic Lymphohistiocytosis (HLH) / Macrophage Activation Syndrome (MAS). Histoplasmosis, the infection mostly associated with HLH, showed a wide variability of BM changes, with or without focal lesions. Leishmaniasis, less often associated with HLH, induced BM changes that mimic myelodysplastic syndrome. BM changes after COVID-19 infection included myeloid and megakaryocytic hypoplasia, erythroid hyperplasia, dyserythropoiesis, hemophagocytosis, and possibly ring granulomas. Other infectious causes included viruses (HHV-8, EBV, Parvovirus B19), mycobacterial infections, and human granulocytic anaplasmosis. HLH may arise in association with the full spectrum of EBV-related disorders, including acute infection, systemic chronic active EBV disease, viral reactivation, and EBV-associated malignancies. BM changes associated with autoimmune diseases included plasmacytosis, myeloid hyperplasia and hemophagocytosis, with or without meeting the criteria of MAS/HLH, the latter often triggered by a secondary infection or exacerbation of the disease. Haematologic malignancies (EBV-positive and negative) with HLH encompassed B-cell, T-/NK-cell, and myeloid neoplasms. In addition, the workshop included therapy-induced BM changes, such as differentiation syndrome, lenalidomide-associated B-ALL, therapy-related dysplasia, gelatinous transformation, CAR-T-induced BM hypoplasia, and CAR-T-associated HLH. Finally, the workshop demonstrated the presence of T-cell expansions in a variety of conditions, which should not be misinterpreted as T-cell malignancy.
| Concepts | Keywords |
|---|---|
| Lymphohistiocytosis | Bone marrow |
| Marrow | Hemophagocytic lymphohistiocytosis |
| Megakaryocytic | Macrophage activation syndrome |
| Viral | Reactive |
| Therapy |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | MAS |
| disease | MESH | included |
| disease | MESH | infections |
| disease | MESH | malignancies |
| disease | MESH | Hemophagocytic Lymphohistiocytosis |
| disease | MESH | Macrophage Activation Syndrome |
| disease | MESH | Histoplasmosis |
| disease | MESH | Leishmaniasis |
| pathway | KEGG | Leishmaniasis |
| disease | MESH | myelodysplastic syndrome |
| disease | MESH | COVID-19 |
| disease | MESH | granulomas |
| disease | MESH | human granulocytic anaplasmosis |
| disease | MESH | disease viral |
| disease | MESH | autoimmune diseases |
| disease | MESH | secondary infection |
| drug | DRUGBANK | Lenalidomide |
| disease | MESH | CAR |